There are 717 resources available
235O - Efficacy and safety of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose: A Subgroup Analysis of A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Presenter: Jianqing Zhu
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
236O - Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial
Presenter: Keiichi Fujiwara
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
237O - Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence for high-grade serous ovarian cancer patients with advanced disease
Presenter: Jing Li
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
238O - Deep learning magnetic resonance imaging radiomic predict platinum-sensitive in patients with epithelial ovarian cancer
Presenter: lei ruilin
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
265O - Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
Presenter: Yihebali Chi
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
266O - Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939
Presenter: Hsiang-Fong Kao
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
267O - Distinct phenotypes of locoregionally advanced (LA-NPC) harbor disparate survival outcomes and are associated with germline variants
Presenter: Enya Ong
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
268MO - A phase-Ib study of lucitanib (AL3810) in a cohort of patients with recurrent and metastatic nasopharyngeal carcinoma (NPC)
Presenter: Hong-yun Zhao
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
269MO - Comparison of three induction chemotherapy regimens with gemcitabine plus cisplatin, cisplatin plus fluorouracil, and cisplatin plus capecitabine for locoregionally advanced nasopharyngeal carcinoma: A pooled analysis of two prospective studies
Presenter: Sik Kwan Chan
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
270MO - A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
Presenter: Li Zhang
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast